Nu Holdings Ltd. (NU) ended the recent trading session at $12.83, demonstrating a -1.53% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. Meanwhile, the Dow lost 0.63%, and the Nasdaq, a tech-heavy index, lost 0.22%. The company's shares have seen an increase of 8.58% over the last month, surpassing the Finance sector's gain of 3.2% and the S&P 500's gain of 4.07%.Analysts and investors alike will be keeping a close eye on the ...

Core Insights - The article compares two stocks in the Medical - Products sector: Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY) to determine which is more attractive to value investors [1] Valuation Metrics - Smith & Nephew has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while EssilorLuxottica has a Zacks Rank of 3 (Hold) [3] - SNN has a forward P/E ratio of 15.83, significantly lower than ESLOY's forward P/E of 35.31, suggesting SNN may be undervalued [5] - The PEG ratio for SNN is 0.96, while ESLOY's PEG ratio is 4.52, indicating SNN's expected earnings growth is more favorable [5] - SNN's P/B ratio is 2.58 compared to ESLOY's P/B of 3.01, further supporting SNN's valuation attractiveness [6] - SNN has a Value grade of A, while ESLOY has a Value grade of D, highlighting SNN's superior valuation metrics [6]

Company Performance - BlackRock (BLK) closed at $1,104.05, marking a +1.41% move from the prior day, outperforming the S&P 500's daily gain of 0.28% [1] - The stock has risen by 9.61% in the past month, leading the Finance sector's gain of 2.79% and the S&P 500's gain of 4.37% [1] Earnings Estimates - BlackRock is set to release its earnings on July 15, 2025, with projected EPS of $10.77, indicating a 3.96% increase year-over-year [2] - Revenue is expected to be $5.38 billion, up 12.02% from the prior-year quarter [2] - For the full year, analysts expect earnings of $45.73 per share and revenue of $22.72 billion, reflecting changes of +4.86% and +11.33% respectively from last year [3] Analyst Sentiment - Recent modifications to analyst estimates for BlackRock indicate changing near-term business trends, with positive revisions reflecting analyst optimism [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks BlackRock at 2 (Buy) [6] Valuation Metrics - BlackRock has a Forward P/E ratio of 23.81, compared to the industry average of 12.15, suggesting it is trading at a premium [7] - The company has a PEG ratio of 3.25, while the average PEG ratio for the Financial - Investment Management industry is 1.42 [8] Industry Context - The Financial - Investment Management industry is part of the Finance sector and holds a Zacks Industry Rank of 62, placing it in the top 26% of all industries [9]

Company Performance - Nutanix (NTNX) closed at $73.61, down 3.84% from the previous trading session, underperforming the S&P 500's gain of 0.28% [1] - Over the past month, Nutanix shares gained 3.35%, lagging behind the Computer and Technology sector's gain of 6.2% and the S&P 500's gain of 4.37% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of $0.31, representing a 14.81% increase year-over-year [2] - Revenue is forecasted to be $642.3 million, indicating a 17.22% growth compared to the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.72 per share and revenue at $2.53 billion, reflecting increases of 31.3% and 17.58% respectively from the previous year [3] - Recent analyst estimate revisions are crucial as they indicate near-term business trends and reflect analyst optimism [3] Analyst Ratings and Valuation - The Zacks Rank system currently rates Nutanix at 3 (Hold), with a recent downward shift of 2.23% in the consensus EPS estimate [5] - Nutanix has a Forward P/E ratio of 44.41, significantly higher than the industry average of 20.02, indicating a premium valuation [6] - The PEG ratio for Nutanix stands at 2.19, compared to the industry average of 2.09 [6] Industry Context - The Computers - IT Services industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Target's stock closed at $104.74, reflecting a +2.26% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.28% [1] - The stock has increased by 4.4% over the past month, leading the Retail-Wholesale sector's gain of 0.87% and the S&P 500's gain of 4.37% [1] Earnings Forecast - Target is expected to report an EPS of $2.08, indicating a 19.07% decrease from the same quarter last year, with a projected quarterly revenue of $24.88 billion, down 2.26% year-over-year [2] - Full-year estimates predict earnings of $7.55 per share and revenue of $104.65 billion, representing year-over-year declines of -14.79% and -1.79%, respectively [3] Analyst Estimates and Rankings - Recent changes in analyst estimates are crucial for investors, as they reflect the evolving business landscape, with positive revisions indicating confidence in performance [3][4] - Target currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.57% over the last 30 days [5] Valuation Metrics - Target's Forward P/E ratio stands at 13.57, which is a discount compared to the industry average of 20.89 [6] - The PEG ratio for Target is 2.93, compared to the Retail - Discount Stores industry's average PEG ratio of 2.76 [6] Industry Context - The Retail - Discount Stores industry is part of the Retail-Wholesale sector and has a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Intel's stock closed at $23.82, with a daily increase of +1.62%, outperforming the S&P 500's gain of 0.28% [1] - Over the past month, Intel's stock has risen by 13.35%, surpassing the Computer and Technology sector's gain of 6.2% and the S&P 500's gain of 4.37% [1] Upcoming Earnings - Intel's earnings report is expected on July 24, 2025, with a forecasted EPS of $0.01, reflecting a 50% decrease from the same quarter last year [2] - Revenue is projected to be $11.87 billion, indicating a 7.53% decline compared to the year-ago quarter [2] Full Year Projections - For the full year, earnings are estimated at $0.28 per share, representing a +315.38% change from the prior year, while revenue is projected at $50.8 billion, showing a -4.33% change [3] Analyst Estimates - Recent modifications to analyst estimates for Intel indicate near-term business trends, with upward revisions suggesting analysts' positivity towards the company's operations [4] - The Zacks Rank system, which reflects these estimate changes, currently rates Intel at 4 (Sell), with a recent downward shift of 3.8% in the EPS estimate [6] Valuation Metrics - Intel's Forward P/E ratio stands at 84.09, significantly higher than the industry average of 39 [7] - The company has a PEG ratio of 8.02, compared to the Semiconductor - General industry's average PEG ratio of 2.72 [7] Industry Context - The Semiconductor - General industry is part of the Computer and Technology sector, holding a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8]

Core Viewpoint - Investors in the Medical - Outpatient and Home Healthcare sector should consider Astrana Health, Inc. (ASTH) as a potentially better value option compared to Chemed (CHE) based on various financial metrics and rankings [1]. Group 1: Zacks Rank and Earnings Outlook - Astrana Health, Inc. has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings estimate revision trend, while Chemed has a Zacks Rank of 4 (Sell) [3]. - The improving earnings outlook for ASTH suggests a favorable investment opportunity compared to CHE [7]. Group 2: Valuation Metrics - ASTH has a forward P/E ratio of 15.66, significantly lower than CHE's forward P/E of 20.47, indicating that ASTH may be undervalued [5]. - The PEG ratio for ASTH is 0.91, while CHE's PEG ratio is 2.09, further suggesting that ASTH offers better value considering expected earnings growth [5]. - ASTH's P/B ratio is 1.85 compared to CHE's P/B of 5.84, reinforcing the notion that ASTH is more attractively priced relative to its book value [6]. - Based on these metrics, ASTH has earned a Value grade of A, while CHE has a Value grade of C [6].

Company Performance - Howmet (HWM) stock increased by 1.09% to $181.42, outperforming the S&P 500's daily gain of 0.61% [1] - Over the past month, Howmet's stock has risen by 6.43%, leading the Aerospace sector's gain of 1.1% and the S&P 500's gain of 3.85% [1] Upcoming Earnings - Howmet is expected to report an EPS of $0.87, reflecting a 29.85% increase from the same quarter last year [2] - Revenue is forecasted to be $1.99 billion, indicating a 5.78% growth compared to the same quarter last year [2] Full Year Estimates - Analysts project earnings of $3.47 per share and revenue of $8.06 billion for the full year, representing increases of 29% and 8.53% respectively from last year [3] - Recent changes to analyst estimates suggest positive sentiment regarding Howmet's business and profitability [3] Analyst Ratings and Valuation - Howmet currently holds a Zacks Rank of 1 (Strong Buy), with a history of outperforming the market [5] - The Forward P/E ratio for Howmet is 51.77, which is a premium compared to the industry average of 24.54 [5] - The PEG ratio for Howmet stands at 2.72, compared to the Aerospace - Defense industry average of 2.05 [6] Industry Context - The Aerospace - Defense industry is ranked 60 in the Zacks Industry Rank, placing it in the top 25% of over 250 industries [6] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - DaVita HealthCare (DVA) closed at $141.84, down 1.36% from the previous trading session, underperforming the S&P 500 which gained 0.61% [1] - Prior to this trading day, DVA shares had increased by 3.37%, outperforming the Medical sector's decline of 0.67% but lagging behind the S&P 500's rise of 3.85% [1] Financial Performance Forecast - DaVita is expected to report an EPS of $2.7, reflecting a 4.25% increase from the same quarter last year [2] - Revenue is forecasted to be $3.3 billion, indicating a 3.5% growth compared to the same quarter last year [2] - For the full year, analysts anticipate earnings of $10.76 per share and revenue of $13.48 billion, representing increases of 11.16% and 5.15% respectively from the previous year [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for DaVita are important as they indicate changing near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks DaVita as 3 (Hold), with the consensus EPS estimate remaining unchanged over the past month [6] Valuation Metrics - DaVita's Forward P/E ratio is 13.37, which is lower than the industry average Forward P/E of 18.96, indicating a valuation discount [7] - The company has a PEG ratio of 0.99, compared to the industry average PEG ratio of 1.8, suggesting that DVA is relatively undervalued based on its expected earnings growth [8] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita, has a Zacks Industry Rank of 39, placing it in the top 16% of over 250 industries [9]

Company Performance - Royal Caribbean (RCL) closed at $333.57, with a +1.02% increase from the previous day, outperforming the S&P 500's gain of 0.61% [1] - The stock has risen by 22.43% over the past month, significantly exceeding the Consumer Discretionary sector's gain of 5.12% and the S&P 500's gain of 3.85% [1] Upcoming Financial Results - The projected earnings per share (EPS) for Royal Caribbean is $4.05, reflecting a 26.17% increase from the same quarter last year [2] - Revenue is expected to reach $4.54 billion, up 10.58% from the prior-year quarter [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $15.43 per share and revenue at $18.05 billion, indicating increases of +30.76% and +9.48% respectively from the previous year [3] - Recent analyst estimate changes suggest a favorable outlook on the company's business health and profitability [3] Valuation Metrics - Royal Caribbean has a Forward P/E ratio of 21.4, which is a discount compared to the industry average Forward P/E of 21.76 [6] - The company holds a PEG ratio of 0.98, compared to the industry average PEG ratio of 1.99 [6] Industry Context - The Leisure and Recreation Services industry, part of the Consumer Discretionary sector, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]